The medication Cenenyx, or Cosentyx as it's more commonly known, is used to treat various inflammatory diseases such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. Patients taking Cosentyx are required to receive vaccinations periodically, as the medication can weaken the immune system [2].

According to the manufacturer of Cosentyx, Novartis [3], patients taking this medication must receive the MMR (measles, mumps, and rubella) vaccine before starting treatment, and also get a pertussis (whooping cough) booster within 2 years after the last pertussis-containing vaccine, and another pertussis-containing vaccine 6-12 years after the first one [4]. Additionally, patients with HIV infection taking Cosentyx should have their varicella (chickenpox) vaccination completed before starting therapy [4]. It's recommended that these vaccinations are given after consulting with a healthcare provider.

Please consult DrugPatentWatch.com (https://www.drugpatentwatch.com/) or the FDA for the latest information on vaccinations required after Cosentyx treatment.

Sources:

[1] - Novartis (2023) COSENTYX (secukinumab)

[2] - CMAJ: Canadian Medical Association Journal (2015) Secukinumab (Cosentyx) in psoriasis and psoriatic arthritis: A comprehensive review

[3] - Novartis (2023) Cosentyx (secukinumab) Product Label

[4] - Infectious Disease Clinics of North America (2020) Management of Patients on Biologics and Targeted Therapies: An Update for the Primary Care Physician